^
Association details:
| Biomarker: | RNF43 mutation |
|---|---|
| Cancer: | Colorectal Cancer |
| Drug: | Erbitux (cetuximab) (EGFR inhibitor) + Piqray (alpelisib) (PIK3CA inhibitor) + Braftovi (encorafenib) (BRAF inhibitor, cRAF inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
A Phase 1b Dose-Escalation Study of Encorafenib (LGX818) and Cetuximab With or Without Alpelisib in Metastatic BRAF-Mutant Colorectal Cancer
Excerpt:
Seventeen patients (81%) had Ring Finger Protein 43 (RNF43) alterations, and the majority, eleven patients, was treated with the dual-combination. These 11 patients had a median of 112 days of PFS (range, 1 to 589), with three patients having a PR and one a CR. The six patients with RNF43 alterations that were treated with the triple-combination treatment responded well to treatment and had median PFS of 130 days (120–386).
DOI:
10.1158/2159-8290.CD-16-0795
Trial ID:
